Literature DB >> 20185635

Suppressors of cytokine signaling abrogate diabetic nephropathy.

Guadalupe Ortiz-Muñoz1, Virginia Lopez-Parra, Oscar Lopez-Franco, Paula Fernandez-Vizarra, Beñat Mallavia, Claudio Flores, Ana Sanz, Julia Blanco, Sergio Mezzano, Alberto Ortiz, Jesus Egido, Carmen Gomez-Guerrero.   

Abstract

Activation of Janus kinase/signal transducers and activators of transcription (JAK/STAT) is an important mechanism by which hyperglycemia contributes to renal damage, suggesting that modulation of this pathway may prevent renal and vascular complications of diabetes. Here, we investigated the involvement of suppressors of cytokine signaling (SOCS) as intracellular negative regulators of JAK/STAT activation in diabetic nephropathy. In a rat model, inducing diabetes resulted in JAK/STAT activation and increased expression of SOCS1 and SOCS3. In humans, we observed increased expression of glomerular and tubulointerstitial SOCS proteins in biopsies of patients with diabetic nephropathy. In vitro, high concentrations of glucose activated JAK/STAT/SOCS in human mesangial and tubular cells. Overexpression of SOCS reversed the glucose-induced activation of the JAK/STAT pathway, expression of STAT-dependent genes (chemokines, growth factors, and extracellular matrix proteins), and cell proliferation. In vivo, intrarenal delivery of adenovirus expressing SOCS1 and SOCS3 to diabetic rats significantly improved renal function and reduced renal lesions associated with diabetes, such as mesangial expansion, fibrosis, and influx of macrophages. SOCS gene delivery also decreased the activation of STAT1 and STAT3 and the expression of proinflammatory and profibrotic proteins in the diabetic kidney. In summary, these results provide direct evidence for a link between the JAK/STAT/SOCS axis and hyperglycemia-induced cell responses in the kidney. Suppression of the JAK/STAT pathway by increasing intracellular SOCS proteins may have therapeutic potential in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185635      PMCID: PMC2865742          DOI: 10.1681/ASN.2009060625

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  46 in total

1.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia.

Authors:  Vemuganti L Raghavendra Rao; Kellie K Bowen; Vinay K Dhodda; Guoqing Song; James L Franklin; Narender R Gavva; Robert J Dempsey
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

3.  Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells.

Authors:  Xiaodan Wang; Seán Shaw; Farhad Amiri; Douglas C Eaton; Mario B Marrero
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

4.  Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose.

Authors:  Farhad Amiri; Seán Shaw; Xiaodan Wang; Jie Tang; Jennifer L Waller; Douglas C Eaton; Mario B Marrero
Journal:  Kidney Int       Date:  2002-05       Impact factor: 10.612

5.  Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes.

Authors:  Shinichi Okada; Kenichi Shikata; Mitsuhiro Matsuda; Daisuke Ogawa; Hitomi Usui; Yuichi Kido; Ryo Nagase; Jun Wada; Yasushi Shikata; Hirofumi Makino
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

6.  Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy.

Authors:  Ting-Chi Lu; Zhao-Hui Wang; Xiaobei Feng; Peter Y Chuang; Wei Fang; Yuhong Shen; David E Levy; Huabao Xiong; Nan Chen; John Cijiang He
Journal:  Kidney Int       Date:  2009-04-08       Impact factor: 10.612

7.  Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.

Authors:  Amy K Banes; Séan Shaw; John Jenkins; Heather Redd; Farhad Amiri; David M Pollock; Mario B Marrero
Journal:  Am J Physiol Renal Physiol       Date:  2003-12-16

Review 8.  Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure.

Authors:  Masaomi Nangaku
Journal:  Intern Med       Date:  2004-01       Impact factor: 1.271

9.  Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation.

Authors:  Paul J Egan; Kate E Lawlor; Warren S Alexander; Ian P Wicks
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

10.  Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation.

Authors:  Silvia F Soriano; Patricia Hernanz-Falcón; José Miguel Rodríguez-Frade; Ana Martín De Ana; Ruth Garzón; Carla Carvalho-Pinto; Antonio J Vila-Coro; Angel Zaballos; Dimitrios Balomenos; Carlos Martínez-A; Mario Mellado
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  72 in total

1.  Discovering hidden relationships between renal diseases and regulated genes through 3D network visualizations.

Authors:  Suresh K Bhavnani; Arunkumaar Ganesan; Theodore Hall; Eric Maslowski; Felix Eichinger; Sebastian Martini; Paul Saxman; Gowtham Bellala; Matthias Kretzler
Journal:  BMC Res Notes       Date:  2010-11-11

2.  Interferon-γ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells.

Authors:  Ryousuke Satou; Kayoko Miyata; Romer A Gonzalez-Villalobos; Julie R Ingelfinger; L Gabriel Navar; Hiroyuki Kobori
Journal:  FASEB J       Date:  2012-02-01       Impact factor: 5.191

Review 3.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

4.  Therapeutic effects of suppressors of cytokine signaling in diabetic nephropathy.

Authors:  Qingjuan Liu; Lingling Xing; Lei Wang; Fang Yao; Shuxia Liu; Jun Hao; Wei Liu; Huijun Duan
Journal:  J Histochem Cytochem       Date:  2013-11-11       Impact factor: 2.479

5.  Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy.

Authors:  T Zhou; X He; R Cheng; B Zhang; R R Zhang; Y Chen; Y Takahashi; A R Murray; K Lee; G Gao; J-X Ma
Journal:  Diabetologia       Date:  2011-10-21       Impact factor: 10.122

6.  PI3K/Akt pathway mediates high glucose-induced lipogenesis and extracellular matrix accumulation in HKC cells through regulation of SREBP-1 and TGF-β1.

Authors:  Jun Hao; Shuxia Liu; Song Zhao; Qingjuan Liu; Xin Lv; Huan Chen; Yunyi Niu; Huijun Duan
Journal:  Histochem Cell Biol       Date:  2011-01-15       Impact factor: 4.304

7.  Fluorofenidone protects against renal fibrosis by inhibiting STAT3 tyrosine phosphorylation.

Authors:  Juan Tang; Chun-yan Liu; Miao-miao Lu; Jing Zhang; Wen-juan Mei; Wen-jun Yang; Yan-yun Xie; Ling Huang; Zhang-zhe Peng; Qiong-jing Yuan; Ji-shi Liu; Gao-yun Hu; Li-jian Tao
Journal:  Mol Cell Biochem       Date:  2015-06-02       Impact factor: 3.396

Review 8.  Targeting STAT3 signaling in kidney disease.

Authors:  Jesse Pace; Praharshasai Paladugu; Bhaskar Das; John C He; Sandeep K Mallipattu
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

Review 9.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

10.  The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation.

Authors:  Jeffrey J Talbot; Xuewen Song; Xiaofang Wang; Markus M Rinschen; Nicholas Doerr; Wells B LaRiviere; Bernhard Schermer; York P Pei; Vicente E Torres; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.